Lanadelumab Active in Angioedema With C1 Inhibitor Deficiency

Share this content:
Lanadelumab Active in Angioedema With C1 Inhibitor Deficiency
Lanadelumab Active in Angioedema With C1 Inhibitor Deficiency

THURSDAY, Feb. 23, 2017 (HealthDay News) -- For patients with hereditary angioedema with C1 inhibitor deficiency, the new kallikrein inhibitor lanadelumab is associated with reduced cleavage of high-molecular-weight kininogen and fewer angioedema attacks, according to a study published in the Feb. 23 issue of the New England Journal of Medicine.

Aleena Banerji, M.D., from Massachusetts General Hospital in Boston, and colleagues conducted a phase 1b trial involving patients with hereditary angioedema with C1 inhibitor deficiency. Participants were randomized to receive lanadelumab (24 patients) or placebo (13 patients) in two administrations 14 days apart with a total dose of 30, 100, 300, or 400 mg.

The researchers observed no discontinuations due to adverse events, serious adverse events, or deaths among patients receiving lanadelumab. There were dose-proportional increases in lanadelumab serum concentrations, with a mean elimination half-life of about two weeks. At a dose of 300 or 400 mg, lanadelumab reduced cleavage of high-molecular-weight kininogen in plasma to levels approaching that of patients without hereditary angioedema with C1 inhibitor deficiency. The 300-mg and 400-mg groups had 100 and 88 percent fewer attacks, respectively, from day eight to day 50 than the placebo group. Twenty-seven percent of patients in the placebo group, and 100 and 82 percent of those in the 300-mg and 400-mg groups, respectively, were attack-free.

"In this small trial, administration of lanadelumab to patients with hereditary angioedema with C1 inhibitor deficiency reduced cleavage of high-molecular-weight kininogen and attacks of angioedema," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Dyax, which manufacturers lanadelumab and funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

ACG: Diphenhydramine Ups Sedation in Chronic Opioid Users

ACG: Diphenhydramine Ups Sedation in Chronic Opioid Users

Improvement in sedation scores for patients using chronic opioids scheduled to undergo colonoscopy

Online Ratings Not Aligned With Objective Quality Measures

Online Ratings Not Aligned With Objective Quality Measures

In addition, consumer ratings are consistent across platforms for specialist physicians

Most Female Physicians Have Faced Sexist Patient Comments

Most Female Physicians Have Faced Sexist Patient Comments

Sexual harassment by patients can negatively affect physician-patient relationship, quality of care

is free, fast, and customized just for you!

Already a member?

Sign In Now »